Abstract
Ifenprodil is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that selectively inhibits receptors containing the NR2B subunit. As such, it has become widely used as a tool to study subtypes of NMDA receptors both in vitro and in vivo, and as a tool for molecular studies of the properties and regulation of NMDA receptors. Ifenprodil has an unusual form of activity-dependence and its mechanism of action may involve an increase in proton inhibition of NMDA receptors. These properties are shared by analogs or derivatives of ifenprodil, some of which may be lead compounds for therapeutically useful NMDA antagonists. Such antagonists have potential as neuroprotectants, anticonvulsants, analgesics, and for the treatment of Parkinsons disease and other disorders of the nervous system. The location of the ifenprodil binding site on NMDA receptors and the structural and mechanistic basis of its effects are still unknown. Recent work suggests that at least part of the ifenprodil binding site is located in the R1 / R2 domain of the NR1 subunit. This region, like the S1 / S2 agonist binding domain, shares homology with bacterial periplasmic binding proteins.
Keywords: NMDA Receptor Antagonist, ifenprodil binding site, MK-801, NR1/NR2 receptors, Proton Inhibition, glycine-independent stimulation, leucine isoleucine valine binding protein (LIVBP)
Current Drug Targets
Title: Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action
Volume: 2 Issue: 3
Author(s): Keith Williams
Affiliation:
Keywords: NMDA Receptor Antagonist, ifenprodil binding site, MK-801, NR1/NR2 receptors, Proton Inhibition, glycine-independent stimulation, leucine isoleucine valine binding protein (LIVBP)
Abstract: Ifenprodil is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that selectively inhibits receptors containing the NR2B subunit. As such, it has become widely used as a tool to study subtypes of NMDA receptors both in vitro and in vivo, and as a tool for molecular studies of the properties and regulation of NMDA receptors. Ifenprodil has an unusual form of activity-dependence and its mechanism of action may involve an increase in proton inhibition of NMDA receptors. These properties are shared by analogs or derivatives of ifenprodil, some of which may be lead compounds for therapeutically useful NMDA antagonists. Such antagonists have potential as neuroprotectants, anticonvulsants, analgesics, and for the treatment of Parkinsons disease and other disorders of the nervous system. The location of the ifenprodil binding site on NMDA receptors and the structural and mechanistic basis of its effects are still unknown. Recent work suggests that at least part of the ifenprodil binding site is located in the R1 / R2 domain of the NR1 subunit. This region, like the S1 / S2 agonist binding domain, shares homology with bacterial periplasmic binding proteins.
Export Options
About this article
Cite this article as:
Williams Keith, Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348489
DOI https://dx.doi.org/10.2174/1389450013348489 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System
Current Neuropharmacology Substance P Regulation in Epilepsy
Current Neuropharmacology Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs
Current HIV Research Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands
Current Medicinal Chemistry - Central Nervous System Agents Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Updated Unified Pharmacophore Model of the Benzodiazepine Binding Site on γ-Aminobutyric Acida Receptors: Correlation with Comparative Models
Current Medicinal Chemistry Current Issues on Epileptic Women
Current Pharmaceutical Design In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) New Prospects for the Drug Treatment of Generalized Anxiety Disorder — A Systematic Review
Current Drug Therapy Fragile X Mental Retardation Protein: Many Partners and Multiple Targets for a Promiscuous Function
Current Genomics Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission
Current Pharmaceutical Design Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives
Letters in Drug Design & Discovery The Role of Oxazolidine Derivatives in the Treatment of Infectious and Chronic Diseases
Current Bioactive Compounds